Relay Therapeutics (RLAY) Free Cash Flow (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Free Cash Flow of -$51.1 million for Q1 2026, up 30.55% year-over-year from -$39.2 million in Q1 2025, and down 13.92% quarter-over-quarter from -$44.9 million in Q4 2025.
Relay Therapeutics (RLAY) Free Cash Flow (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Free Cash Flow for 8 consecutive years, with -$51.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 30.55% year-over-year to -$51.1 million; the TTM figure through Mar 2026 stood at -$213.4 million (up 21.73% YoY), while the FY2025 annual figure was -$235.9 million, up 6.08% from the prior year.
- Free Cash Flow eased to -$51.1 million in Q1 2026 per RLAY's latest filing, from -$44.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$44.9 million in Q4 2025 and bottomed at -$89.3 million in Q4 2023.
- Historically, Free Cash Flow has averaged -$63.6 million across 5 years, with a median of -$62.1 million in 2025.
- Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 212.57% — and 2024, when it soared 35.2%.
- Relay Therapeutics' Free Cash Flow stood at -$59.4 million in 2022, then tumbled by 50.36% to -$89.3 million in 2023, then jumped by 35.2% to -$57.9 million in 2024, then advanced by 22.47% to -$44.9 million in 2025, then retreated by 13.92% to -$51.1 million in 2026.
- Business Quant data shows RLAY's Free Cash Flow at -$51.1 million in Q1 2026, -$44.9 million in Q4 2025, and -$62.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | -54.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54.11 Mn |
| Jun 30, 2026 | -54.11 Mn |
| Mar 31, 2026 | -51.11 Mn |
| Mar 31, 2026 | -51.11 Mn |
| Dec 31, 2025 | -44.87 Mn |
| Dec 31, 2025 | -44.87 Mn |
| Sep 30, 2025 | -62.12 Mn |
| Sep 30, 2025 | -62.12 Mn |
| Jun 30, 2025 | -55.29 Mn |
| Jun 30, 2025 | -55.29 Mn |
| Mar 31, 2025 | -73.59 Mn |
| Mar 31, 2025 | -73.59 Mn |
| Dec 31, 2024 | -57.87 Mn |
| Dec 31, 2024 | -57.87 Mn |
| Sep 30, 2024 | -75.31 Mn |
| Sep 30, 2024 | -75.31 Mn |
| Jun 30, 2024 | -65.84 Mn |
| Jun 30, 2024 | -65.84 Mn |
| Mar 31, 2024 | -52.10 Mn |
| Mar 31, 2024 | -52.10 Mn |